# Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

> **NCT03266627** · PHASE2 · RECRUITING · sponsor: **New York Medical College** · enrollment: 20 (estimated)

## Conditions studied

- Adenovirus
- Primary Immune Deficiency Disorder

## Interventions

- **DRUG:** cytotoxic t-lymphocytes

## Key facts

- **NCT ID:** NCT03266627
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03266627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03266627, "Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03266627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*